MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery.

We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days that are designed and characterized in silico and validated with state-of-the-art biological technologies.

While MAbSilico combines 3D modeling, interaction simulations and linear sequence analysis, the antibody drug candidates are defined based on their epitope, affinity, off-target risk, cross-species reactivity and developability to be ready for biological activity evaluation.

Using NLP technologies we gather information about antibodies and their targets in different databases to ensure competitive landscape analysis and the freedom to operate of the computationally designed antibody candidates.